Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04345692 · ClinicalTrials.gov registry record · Phase 3
A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients
A Phase 3 study, sponsored by Queen's Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT04345692 is a Phase 3 study that was terminated before completion, run by Queen's Medical Center. The registered enrollment target is 17 participants.
The verdict
NCT04345692, a Phase 3 study, was terminated before completion, sponsored by Queen's Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study is a randomized, open label clinical trial to evaluate the safety and efficacy of hydroxychloroquine (HCQ) plus usual care compared to usual care in approximately 350 hospitalized patients diagnosed with COVID-19. The study will be a 2-arm, non-blinded comparison between open label hydroxychloroquine and usual care. The course of treatment (HCQ) is five days. Participants will be followed to study day 28.
Interventions
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-03-26 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04345692
The ClinicalTrials.gov registry entry for NCT04345692 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Queen's Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydroxychloroquine is the first listed.
NCT04345692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04345692 about?
NCT04345692 is a clinical study titled "A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients". This study is a randomized, open label clinical trial to evaluate the safety and efficacy of hydroxychloroquine (HCQ) plus usual care compared to usual care in approximately 350 hospitalized patients diagnosed with COVID-19. The study will be a 2-arm, non-blinded comparison between open label hydrox...
What is the current status of trial NCT04345692?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2020-03-26. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT04345692?
The interventions under investigation include: Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04345692?
This trial is sponsored by Queen's Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.